Boxer Capital LLC Continues to Hold Stake in Nabriva Therapeutics AG (NBRV)

Boxer Capital LLC maintained its stake in Nabriva Therapeutics AG (NASDAQ:NBRV) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 176,710 shares of the biotechnology company’s stock at the end of the first quarter. Nabriva Therapeutics AG makes up 0.5% of Boxer Capital LLC’s investment portfolio, making the stock its 22nd largest position. Boxer Capital LLC’s holdings in Nabriva Therapeutics AG were worth $2,121,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vivo Capital LLC raised its stake in Nabriva Therapeutics AG by 27.6% in the fourth quarter. Vivo Capital LLC now owns 4,021,559 shares of the biotechnology company’s stock valued at $23,968,000 after buying an additional 869,859 shares during the last quarter. Novo A S raised its stake in Nabriva Therapeutics AG by 108.3% in the fourth quarter. Novo A S now owns 2,326,544 shares of the biotechnology company’s stock valued at $13,866,000 after buying an additional 1,209,884 shares during the last quarter. Wellington Management Group LLP raised its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the last quarter. Orbimed Advisors LLC raised its stake in Nabriva Therapeutics AG by 27.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,677,940 shares of the biotechnology company’s stock valued at $10,001,000 after buying an additional 362,940 shares during the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in Nabriva Therapeutics AG during the first quarter valued at approximately $2,074,000. 55.90% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded up 2.91% on Friday, reaching $9.20. 15,843 shares of the company’s stock traded hands. The company’s market cap is $250.33 million. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $12.75. The stock has a 50-day moving average price of $9.97 and a 200-day moving average price of $9.10.

ILLEGAL ACTIVITY NOTICE: “Boxer Capital LLC Continues to Hold Stake in Nabriva Therapeutics AG (NBRV)” was first published by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.wkrb13.com/markets/2228922/boxer-capital-llc-continues-to-hold-stake-in-nabriva-therapeutics-ag-nbrv.html.

NBRV has been the topic of several research reports. Wedbush reissued an “outperform” rating and set a $13.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research note on Monday, June 5th. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Saturday, May 27th. HC Wainwright reissued a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, March 27th. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $15.29.

In related news, Director George Harrison Talbot sold 325 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total value of $32,682.00. Following the completion of the transaction, the director now directly owns 3,854 shares of the company’s stock, valued at approximately $387,558.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 32,831 shares of the stock in a transaction that occurred on Thursday, April 13th. The shares were sold at an average price of $11.24, for a total transaction of $369,020.44. Following the completion of the transaction, the insider now directly owns 2,660,689 shares of the company’s stock, valued at $29,906,144.36. The disclosure for this sale can be found here. Insiders sold a total of 166,703 shares of company stock worth $1,911,919 over the last 90 days.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Want to see what other hedge funds are holding NBRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nabriva Therapeutics AG (NASDAQ:NBRV).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228922/boxer-capital-llc-continues-to-hold-stake-in-nabriva-therapeutics-ag-nbrv.html

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.